Pfizer

This is an excerpt from Medically Necessary, a health care supply chain newsletter. Subscribe here. The news: A panel advising the Food and Drug Administration recommended approving COVID-19 booster shots only for people over age 65 and people who have a high risk of developing severe COVID-19...

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five...

On Sunday, President Joe Biden's Chief Medical Adviser Dr. Anthony Fauci said officials would soon get the regulatory clearance to administer Covid-19 vaccine booster shots made by Pfizer Inc (NYSE: PFE). However, the Moderna Inc (NASDAQ: MRNA) booster could take a little...

Wana Brands, the pioneering edibles manufacturer, is partnering with Medicine Man dispensaries along with the Colorado Dept. of Public Health and Environment (CDPHE) to host a series of COVID-19 vaccination clinics throughout the Denver metro area during Wana's Summer...

Last week, Reuters reported that Airbnb (NASDAQ: ABNB) has offered to provide free, temporary housing to 20,000 Afghan refugees across the globe, helping its shares close up 10% after the announcement. Last Thursday, the company revealed it will allow anyone with available space to sign up to...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Last week's bullish calls included a top COVID-19 vaccine play, a recent high-profile IPO and a trendy retailer. The apex cryptocurrency, two big automakers and an upscale retailer were among the...

After another big rally to start the week, what can Wall Street do for an encore?  Maybe not a lot, at least for the moment. Stocks moved up just a bit in pre-market trading. It looks early like there might be a chance for small gains on top of what happened yesterday, but a lack of major new...

Investors may be scratching their heads at the resiliency shown by the major U.S. stock indices as of late. Despite the Delta variant unleashing renewed fears of economic shutdowns globally and other factors that should be dampening markets – supply chain issues, labor and semiconductor...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and...

This weekend's Barron's cover story examines the long-term prospects for big tech companies currently in the sights of regulators and lawmakers. Other featured articles discuss what the ongoing COVID-19 threat means for drugmakers and why investors so often fail to understand how to value...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Last week's bullish calls included top growth and reopening stocks. Automakers and a leading cryptocurrency play were among the bearish calls seen. The Dow Jones industrial average posted about a 1%...

Besides proudly stating that its Covid-19 shot produced a "robust" antibody response against the highly contagious delta variant last Thursday, Moderna (NASDAQ: MRNA) also posted second-quarter financial results that beat Wall Street's expectations on both earnings and revenue. Q2...

The cover story in this weekend's Barron's suggests how to play travel stocks as the recovery falters. Other featured articles discuss banking stocks with steady dividends, stocks that will benefit from share buybacks and why the boom in energy stocks may be over. Also, see the prospects...

These days, Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are swimming in real money and they have COVID-19 to thank. Since the beginning of April, Moderna and BioNTech (NASDAQ: BNTX) saw their shares go up about 80% and 100%, respectively. Much of that climb has been on the assumption...

Benzinga has examined the prospects for many of investors' favorite stocks over the past week. The past week's bullish calls included a couple of FAANG stocks and a company that just took a big hit. The iPhone maker, a COVID-19 vaccine play and a cryptocurrency-related stock were...